Literature DB >> 26671992

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

Himisha Beltran1, Adam Jendrisak2, Mark Landers2, Juan Miguel Mosquera3, Myriam Kossai4, Jessica Louw2, Rachel Krupa2, Ryon P Graf2, Nicole A Schreiber5, David M Nanus6, Scott T Tagawa6, Dena Marrinucci2, Ryan Dittamore2, Howard I Scher5.   

Abstract

PURPOSE: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR) signaling independent phenotype can occur in the later stages of the disease and is associated with low AR expression +/- the development of small-cell or neuroendocrine tumor characteristics. As metastatic tumor biopsies are not always feasible and are difficult to repeat, we sought to evaluate noninvasive methods to identify patients transitioning toward a neuroendocrine phenotype (NEPC). EXPERIMENTAL
DESIGN: We prospectively studied a metastatic tumor biopsy, serum biomarkers, and circulating tumor cells (CTC, Epic Sciences) from patients with castration-resistant prostate cancer (CRPC) including those with pure or mixed NEPC histology present on biopsy. CTCs labeled with the patient's clinical status were used to learn features that discriminate NEPC patients, which was then applied to an independent cohort.
RESULTS: Twenty-seven patients with CRPC including 12 NEPC and 5 with atypical clinical features suggestive of NEPC transition were studied. CTCs from NEPC patients demonstrated frequent clusters, low or absent AR expression, lower cytokeratin expression, and smaller morphology relative to typical CRPC. A multivariate analysis of protein and morphologic variables enabled distinguishing CTCs of NEPC from CRPC. This CTC classifier was applied to an independent prospective cohort of 159 metastatic CRPC patients and identified in 17/159 (10.7%) of cases, enriched in patients with high CTC burden (P < 0.01) and visceral metastases (P = 0.04).
CONCLUSIONS: CTCs from patients with NEPC have unique morphologic characteristics, which were also identified in a subset of CRPC patients with aggressive clinical features potentially undergoing NEPC transition. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26671992      PMCID: PMC4990782          DOI: 10.1158/1078-0432.CCR-15-0137

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.

Authors:  Dena Marrinucci; Kelly Bethel; Anand Kolatkar; Madelyn S Luttgen; Michael Malchiodi; Franziska Baehring; Katharina Voigt; Daniel Lazar; Jorge Nieva; Lyudmila Bazhenova; Andrew H Ko; W Michael Korn; Ethan Schram; Michael Coward; Xing Yang; Thomas Metzner; Rachelle Lamy; Meghana Honnatti; Craig Yoshioka; Joshua Kunken; Yelena Petrova; Devin Sok; David Nelson; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

2.  European cancer mortality predictions for the year 2014.

Authors:  M Malvezzi; P Bertuccio; F Levi; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2014-04-23       Impact factor: 32.976

3.  Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

Authors:  Colin S Cooper; Rosalind Eeles; David C Wedge; Peter Van Loo; Gunes Gundem; Ludmil B Alexandrov; Barbara Kremeyer; Adam Butler; Andrew G Lynch; Niedzica Camacho; Charlie E Massie; Jonathan Kay; Hayley J Luxton; Sandra Edwards; Zsofia Kote-Jarai; Nening Dennis; Sue Merson; Daniel Leongamornlert; Jorge Zamora; Cathy Corbishley; Sarah Thomas; Serena Nik-Zainal; Manasa Ramakrishna; Sarah O'Meara; Lucy Matthews; Jeremy Clark; Rachel Hurst; Richard Mithen; Robert G Bristow; Paul C Boutros; Michael Fraser; Susanna Cooke; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Hinton; Jon Teague; Stuart McLaren; Laura Mudie; Claire Hardy; Elizabeth Anderson; Olivia Joseph; Victoria Goody; Ben Robinson; Mark Maddison; Stephen Gamble; Christopher Greenman; Dan Berney; Steven Hazell; Naomi Livni; Cyril Fisher; Christopher Ogden; Pardeep Kumar; Alan Thompson; Christopher Woodhouse; David Nicol; Erik Mayer; Tim Dudderidge; Nimish C Shah; Vincent Gnanapragasam; Thierry Voet; Peter Campbell; Andrew Futreal; Douglas Easton; Anne Y Warren; Christopher S Foster; Michael R Stratton; Hayley C Whitaker; Ultan McDermott; Daniel S Brewer; David E Neal
Journal:  Nat Genet       Date:  2015-06       Impact factor: 38.330

4.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Scott T Tagawa; Kyung Park; Theresa MacDonald; Matthew I Milowsky; Juan Miguel Mosquera; Mark A Rubin; David M Nanus
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

5.  Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle.

Authors:  Scott T Tagawa
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

Review 6.  Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.

Authors:  Rahul Aggarwal; Tian Zhang; Eric J Small; Andrew J Armstrong
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

Review 7.  Aggressive variants of castration-resistant prostate cancer.

Authors:  Himisha Beltran; Scott Tomlins; Ana Aparicio; Vivek Arora; David Rickman; Gustavo Ayala; Jiaoti Huang; Lawrence True; Martin E Gleave; Howard Soule; Christopher Logothetis; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

8.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Authors:  Christos N Papandreou; Danai D Daliani; Peter F Thall; Shi-Ming Tu; Xuemei Wang; Adriana Reyes; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

9.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 10.  Circulating tumor cells: a multifunctional biomarker.

Authors:  Timothy A Yap; David Lorente; Aurelius Omlin; David Olmos; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-05-15       Impact factor: 12.531

View more
  57 in total

Review 1.  CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.

Authors:  Diogo A Bastos; Emmanuel S Antonarakis
Journal:  Expert Rev Mol Diagn       Date:  2018-01-16       Impact factor: 5.225

2.  Using circulating tumor cells to advance precision medicine in prostate cancer.

Authors:  Giuseppe Galletti; Daniel Worroll; David M Nanus; Paraskevi Giannakakou
Journal:  J Cancer Metastasis Treat       Date:  2017-09-27

3.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.

Authors:  Loredana Puca; Katie Gavyert; Verena Sailer; Vincenza Conteduca; Etienne Dardenne; Michael Sigouros; Kumiko Isse; Megan Kearney; Aram Vosoughi; Luisa Fernandez; Heng Pan; Samaneh Motanagh; Judy Hess; Adam J Donoghue; Andrea Sboner; Yuzhuo Wang; Ryan Dittamore; David Rickman; David M Nanus; Scott T Tagawa; Olivier Elemento; Juan Miguel Mosquera; Laura Saunders; Himisha Beltran
Journal:  Sci Transl Med       Date:  2019-03-20       Impact factor: 17.956

4.  Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.

Authors:  Daniel J Boffa; Ryon P Graf; Michelle C Salazar; Jessica Hoag; David Lu; Rachel Krupa; Jessica Louw; Lyndsey Dugan; Yipeng Wang; Mark Landers; Mahipal Suraneni; Stephanie B Greene; Marisa Magaña; Samir Makani; Lyudmila Bazhenova; Ryan V Dittamore; Jorge Nieva
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04-26       Impact factor: 4.254

Review 5.  Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Authors:  Guilhem Roubaud; Bobby C Liaw; William K Oh; David J Mulholland
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

Review 6.  Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.

Authors:  Gareth J Morrison; Amir Goldkorn
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

7.  Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.

Authors:  Paymaneh D Malihi; Ryon P Graf; Angel Rodriguez; Naveen Ramesh; Jerry Lee; Ramsay Sutton; Rhett Jiles; Carmen Ruiz Velasco; Emi Sei; Anand Kolatkar; Christopher Logothetis; Nicholas E Navin; Paul Corn; Ana M Aparicio; Ryan Dittamore; James Hicks; Peter Kuhn; Amado J Zurita
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

Review 8.  Emerging Variants of Castration-Resistant Prostate Cancer.

Authors:  Panagiotis J Vlachostergios; Loredana Puca; Himisha Beltran
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 9.  The Cohesive Metastasis Phenotype in Human Prostate Cancer.

Authors:  William L Harryman; James P Hinton; Cynthia P Rubenstein; Parminder Singh; Raymond B Nagle; Sarah J Parker; Beatrice S Knudsen; Anne E Cress
Journal:  Biochim Biophys Acta       Date:  2016-09-24

Review 10.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance.

Authors:  Álvaro Quintanal-Villalonga; Joseph M Chan; Helena A Yu; Dana Pe'er; Charles L Sawyers; Triparna Sen; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2020-03-09       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.